Jaroslaw Bilinski

Jaroslaw Bilinski


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2021 in Gut
Verified
Journal Article
Open access
PDF file
JBJaroslaw Bilinski
Jaroslaw Bilinski
KWKatarzyna Winter
Katarzyna Winter
MJMarcin Jasiński
Marcin Jasiński
ASAnna Szczęś
Anna Szczęś
NBNatalia Bilinska
Natalia Bilinska
GBGrzegorz W Basak
Grzegorz W Basak

16 December 2020 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
JBJaroslaw Bilinski
Jaroslaw Bilinski
KLKarol Lis
Karol Lis
ATAgnieszka Tomaszewska
Agnieszka Tomaszewska
PGPawel Grzesiowski
Pawel Grzesiowski
TDTomasz Dzieciatkowski
Tomasz Dzieciatkowski
GBGrzegorz W. Basak
Grzegorz W. Basak
Click on the article title to read more.

27 September 2022 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
XQXiaoying Qiao
Xiaoying Qiao
JBJaroslaw Bilinski
Jaroslaw Bilinski
LWLeyi Wang
Leyi Wang
TYTianyu Yang
Tianyu Yang
RLRongmu Luo
Rongmu Luo
GYGuibin Yang
Guibin Yang

29 September 2021 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
JBJaroslaw Bilinski
Jaroslaw Bilinski
MJMarcin Jasiński
Marcin Jasiński
ATAgnieszka Tomaszewska
Agnieszka Tomaszewska
KLKarol Lis
Karol Lis
PKPiotr Kacprzyk
Piotr Kacprzyk
GBGrzegorz W. Basak
Grzegorz W. Basak
Click on the article title to read more.

1 April 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
JBJaroslaw Bilinski
Jaroslaw Bilinski
MJMarcin Jasinski
Marcin Jasinski
GBGrzegorz Wladyslaw Basak
Grzegorz Wladyslaw Basak
The number of allogeneic hematopoietic stem cell transplantations conducted worldwide is constantly rising. Together with that, the absolute number of complications after the procedure is increasing, with graft-versus-host disease (GvHD) being one of the most common. The standard treatment is steroid administration, but only 40–60% of patients will respond to the therapy and some others will be steroid-dependent. There is still no consensus regarding the best second-line option, but fecal microbiota transplantation (FMT) has shown encouraging preliminary and first clinically relevant results in recent years and seems to offer great hope for patients. The reason for treatment of steroid-resistant acute GvHD using this method derives from studies showing the significant immunomodulatory role played by the intestinal microbiota in the pathogenesis of GvHD. Depletion of commensal microbes is accountable for aggravation of the disease and is associated with decreased overall survival. In this review, we present the pathogenesis of GvHD, with special focus on the special role of the gut microbiota and its crosstalk with immune cells. Moreover, we show the results of studies and case reports to date regarding the use of FMT in the treatment of steroid-resistant acute GvHD.

23 June 2020 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
JBJaroslaw Bilinski
Jaroslaw Bilinski
KLKarol Lis
Karol Lis
ATAgnieszka Tomaszewska
Agnieszka Tomaszewska
APAleksandra Pechcinska
Aleksandra Pechcinska
PGPawel Grzesiowski
Pawel Grzesiowski
GBGrzegorz Wladyslaw Basak
Grzegorz Wladyslaw Basak